Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.43 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.41 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.38 |
| ▸ | RRM1 | P23921 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21257350 | 0.93 | KMT2A (0.49) | KMT2ACYP2D6CYP2C9CYP2C19ANPEP | |
| SCHEMBL25542575 | 0.91 | ALDH1A2 (0.48) | KMT2ACYP2D6CYP2C9CYP2C19ANPEP | |
| SCHEMBL23442882 | 0.91 | ALDH1A2 (0.48) | KMT2ACYP2D6CYP2C9CYP2C19ANPEP | |
| SCHEMBL21303532 | 0.91 | ALDH1A2 (0.48) | KMT2ACYP2D6CYP2C9CYP2C19ANPEP | |
| SCHEMBL11129 | 0.86 | ANPEP (0.55) | KMT2ACYP2D6CYP2C9CYP2C19ANPEP | |
| SCHEMBL22917014 | 0.85 | KMT2A (0.57) | KMT2ACYP2D6CYP2C9CYP2C19ALDH1A2 | |
| SCHEMBL861034 | 0.85 | KMT2A (0.57) | KMT2ACYP2D6CYP2C9CYP2C19ALDH1A2 | |
| SCHEMBL24508453 | 0.85 | KMT2A (0.46) | KMT2ACYP2D6CYP2C9CYP2C19ANPEP | |
| SCHEMBL25632154 | 0.84 | KMT2A (0.53) | KMT2ACYP2D6CYP2C9CYP2C19ANPEP | |
| SCHEMBL23188735 | 0.83 | ALDH1A1 (0.58) | KMT2ACYP2D6CYP2C9CYP2C19ALDH1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238440-A1 | PREPARATION METHOD FOR AND APPLICATION OF ANTIBODY CONJUGATED DRUG | HYSLINK THERAPEUTICS (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| WO-2024006477-A1 | MULTIPLEX DYE COMPOUNDS | Life Technologies Corporation (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230295437-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS | Singular Genomics Systems, Inc. | 2023-09-21 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-8461128-B2 | Anti-microbial agents and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120214807-A1 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120208818-A1 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208818-A1 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8067457-B2 | Compounds useful as antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067415-B2 | Compounds useful as antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100016289-A1 | Compounds Useful as Antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20090197884-A1 | Compounds Useful as Antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090170805-A1 | ANTI-MICROBIAL AGENTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | disclosed |
| US-20090163497-A1 | Compounds Useful as Antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214807-A1 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | CCR2, CCR1, CXCR3 | KMT2A 2225/4885CYP2D6 1977/4885CYP2C9 2143/4885 |
| US-20100016289-A1 | Compounds Useful as Antagonists of CCR2 | CCR2, CCR1, CXCR3 | KMT2A 2789/4885CYP2D6 2149/4885CYP2C9 2338/4885 |
| US-20230295437-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS | AS3MT, SCLY, NASP | KMT2A 3136/4885CYP2D6 3294/4885CYP2C9 3372/4885 |
| US-20090197884-A1 | Compounds Useful as Antagonists of CCR2 | CCR2, CCR1, CXCR3 | KMT2A 2225/4885CYP2D6 1977/4885CYP2C9 2143/4885 |
| US-20090163497-A1 | Compounds Useful as Antagonists of CCR2 | CCR2, CCR1, CXCR3 | KMT2A 2315/4885CYP2D6 1774/4885CYP2C9 1779/4885 |
| US-20120208818-A1 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | CCR2, CCR1, CXCR3 | KMT2A 2225/4885CYP2D6 1977/4885CYP2C9 2143/4885 |
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PLTP, LNPK, PLIN3 | KMT2A 4165/4885CYP2D6 4822/4885CYP2C9 4806/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | KMT2A 737/4885CYP2D6 698/4885CYP2C9 439/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KMT2A 445/4885CYP2D6 3599/4885CYP2C9 3608/4885 |
| US-20240238440-A1 | PREPARATION METHOD FOR AND APPLICATION OF ANTIBODY CONJUGATED DRUG | SI, MET, MTX1 | KMT2A 3572/4885CYP2D6 154/4885CYP2C9 435/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KMT2A 445/4885CYP2D6 3599/4885CYP2C9 3608/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KMT2A 445/4885CYP2D6 3599/4885CYP2C9 3608/4885 |
| US-20090170805-A1 | ANTI-MICROBIAL AGENTS AND USES THEREOF | ACAT1, ACAT2, APEH | KMT2A 1694/4885CYP2D6 3894/4885CYP2C9 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.